Rekvina Laboratories Board Recommends Open Offer is Fair and Reasonable Amid Acquisition Drive
The Committee of Independent Directors (IDC) of Rekvina Laboratories Limited has issued a recommendation stating that the open offer being conducted by three acquirers is fair and reasonable, advising public shareholders in connection with the proposed acquisition.The company confirmed that the open offer aims to acquire up to 28,90,100 equity shares of Rekvina Laboratories Limited (the "Target Company"). The open offer was launched by Surbhit Mukesh Shah (Acquirer 1), Amit Mukesh Shah (Acquirer 2), and Dhruvalkumar Patel (Acquirer 3).
The IDC found that the offer price of ₹10 per equity share is fair and reasonable, especially when compared to the current trading price. The recommendation was made following a review of the company's relevant details concerning the proposed acquisition.
Key Details of the Open Offer
The open offer commenced on June 12, 2026, and concluded on June 25, 2026. The IDC report provided a summary of reasons for its recommendation, including the comparison between the offer price and market valuation factors.The relevant timeline for the open offer is detailed below:
| Activity | Original Date | Revised Date (If Applicable) |
|---|---|---|
| Public Announcement | March 16, 2026 | N/A |
| Offer Opening Date | June 12, 2026 | N/A |
| Offer Closure Date | June 25, 2026 | N/A |
| Payment of Consideration | July 10, 2026 | August 4, 2026 |
The IDC, which included members Jay Chintan Patel (Chairman), Pratek Jain (Member), and two other Independent Directors, reviewed the offer in accordance with SEBI regulations concerning substantial acquisitions of shares and takeovers.
One of the key findings from the recommendation was that the offer price of ₹10 per equity share is fair and reasonable, noting that this amount is higher than the current trading price.
For any questions regarding the open offer, shareholders are advised to consult the public announcement dated March 16, 2026, and related materials published in financial newspapers.
Stock Price Movement
As of 12:14, shares of Rekvina Laboratories Ltd are slipping lower, trading at ₹35.50 after declining by 1.33%. The stock has moved within a tight intraday range, having touched a low of ₹35.27 against an intraday high of ₹35.50.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.